Cipla Limited (NSE:CIPLA)
India
· Delayed Price · Currency is INR | Market Cap | 1.16T |
| Revenue (ttm) | 267.20B |
| Net Income (ttm) | 49.90B |
| Shares Out | 807.62M |
| EPS (ttm) | 61.74 |
| PE Ratio | 23.36 |
| Forward PE | 23.77 |
| Dividend | 13.00 (0.88%) |
| Ex-Dividend Date | Aug 2, 2024 |
| Volume | 1,495,848 |
| Average Volume | 1,476,607 |
| Open | 1,475.00 |
| Previous Close | 1,482.90 |
| Day's Range | 1,434.45 - 1,478.65 |
| 52-Week Range | 1,317.25 - 1,702.05 |
| Beta | 0.30 |
| RSI | 51.80 |
| Earnings Date | May 9, 2025 |
About Cipla
Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormaliti... [Read more]
Financial Performance
In 2023, Cipla's revenue was 255.37 billion, an increase of 13.20% compared to the previous year's 225.59 billion. Earnings were 41.22 billion, an increase of 47.10%.
Financial StatementsNews
Nifty 50 top losers today, March 26: NTPC, Tech Mahindra, Cipla, Bajaj Finance and more
The Indian stock market ended in the red on Wednesday as both Sensex and Nifty reversed their early gains. The benchmark indices, which opened on a positive note for the eighth consecutive session, to...
Cipla signs pact with Taiwan drug firm
India Business News: Cipla has announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to market clobetasol propionate ophthalmic suspension 0.
Cipla and Formosa Pharmaceuticals sign multi-regional licensing deal for clobetasol suspension
Cipla Limited has entered into an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to commercialize clobetasol propionate ophthalmic suspension, 0.05% across 11 countries. This ...
Nifty 50 top gainers today, March 13: Bharat Electronics, State Bank of India, ONGC, Cipla and more
On March 13, Indian equity indices ended on a negative note, with the benchmark indices struggling to maintain upward momentum. The BSE Sensex dropped 200.85 points or 0.27% to close at 73,828.91, whi...
Macquarie bullish on select pharma and CDMO stocks, bearish on hospitals
Macquarie believes that the recent correction in pharma stocks due to US tariff threats provides an attractive buying opportunity, particularly in formulations and CDMO (Contract Development and Manuf...
Top stocks to watch today on February 21: Cipla, NTPC Green Energy, RVNL, Delta Corp, HG Infra and more
The Indian stock market is expected to have a weak start today, with benchmark indices likely to open lower. At 8:32 AM, GIFT Nifty futures traded down by 61.5 points at 22,854, indicating bearish sen...
Stocks to watch today on 21 Feb: Cipla, Senores, Narayana Hrudayalaya, Sanofi in pharmaceuticals and healthcare sector
The pharmaceuticals and healthcare sector is witnessing significant advancements with new product approvals, strategic acquisitions, and expansions. Key stocks to watch today are: Cipla: Received USFD...
Cipla’s subsidiary Sitec Labs receives two observations from USFDA after inspection
Cipla Limited announced that the United States Food and Drug Administration (USFDA) has completed its current Good Manufacturing Practices (cGMP) inspection at the analytical testing facility of Sitec...
Cipla receives USFDA approval for Nilotinib Capsules 50, 150 and 200 mg
Cipla Limited has announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its New Drug Application (NDA) for Nilotinib Capsules 50, 150, and 200 m...
Cipla shares drop nearly 3% after USFDA inspection classified as Voluntary Action Indicated (VAI)
Shares of Cipla Ltd fell nearly 3% today, trading at ₹1,434.85, marking a decline of ₹37.40 or 2.54%, following the announcement that the United States Food and Drug Administration (USFDA) has classif...
Stocks to watch today on February 10: LIC, M&M, Bharat Electronics, Glenmark, Vedanta, Cipla, NHPC, Oil India & more in focus
The Indian stock market is set to witness key movements on February 10, with several companies announcing their Q3FY25 earnings and significant corporate developments. From Bharat Electronics’ major d...
Cipla receives “VAI” classification from USFDA for manufacturing facility in Virgonagar
Cipla Limited has announced that the United States Food and Drug Administration (USFDA) has classified its recent inspection at the company’s manufacturing facility in Virgonagar, Bengaluru, as “Volun...
Nifty 50 top gainers today on February 6: Cipla, ITC Hotels, Dr. Reddy’s Laboratories, HDFC Life and more
The Indian equity markets faced a downward trend on February 6, with major indices ending in the red. The Nifty 50 concluded the session at 23,603.35, experiencing a decline of 138.05 points, or 0.39%...
Cipla stock: Buy, Sell, or Hold? What top brokerages say post Q3 results
Brokerages remain bullish on Cipla after its Q3 FY25 results, highlighting strong earnings, improving margins, and upcoming US launches. Both HSBC and Nomura have maintained a ‘Buy’ rating on the stoc...
HSBC maintains ‘Buy’ on Cipla, sees 26% upside as Q3 beats estimates
HSBC has reiterated its Buy rating on Cipla, with a target price of ₹1,800 per share, implying a 26% upside from the current market price of ₹1,427.00. The company’s Q3 PAT surpassed estimates, driven...
Nomura maintains ‘Buy’ on Cipla, sees 25% upside despite US launch delays
Nomura has reiterated its Buy rating on Cipla, setting a target price of ₹1,780 per share, implying a 25% upside from the current market price of ₹1,427.00. The company’s Q3 earnings came in ahead of ...
Cipla Q3 FY25 results: Revenue at Rs 7,073 crore (+8% YoY), profit surges 50% YoY to Rs 1,571 crore
Cipla Limited has reported its highest-ever quarterly revenue of ₹7,073 crore in Q3 FY25, reflecting an 8% year-on-year (YoY) growth. The company’s EBITDA stood at ₹1,989 crore, marking a 16% YoY incr...
Cipla receives one USFDA observation for Goa facility inspection
Cipla Ltd. has announced that the United States Food and Drug Administration (USFDA) conducted an inspection at its wholly-owned subsidiary, Medispray Laboratories Private Limited, in Kundaim, Goa, fr...
Top stocks to watch in trade today: Hero MotoCorp, Cipla, Blue Dart, ASK Auto, Optiemus, Sula Vineyards, Hathway Cable, MTNL, Innova Captab and more
Stocks in focus for January 15, 2025 Hero MotoCorp: Launches the new Destini 125 in three variants, starting at Rs 80,450. Cipla: Tax demand revised to Rs 559 crore from Rs 773 crore for AY 2016-2023....
Pharma stocks: Dr. Reddy’s up 1.70%, Biocon down 2.17%, Lupin falls 2.18%
As of 10:58 AM, pharma stocks exhibited mixed performance. Here are the key highlights: Gainers: Dr. Reddy’s Laboratories: Leading the gains with a 1.70% rise, trading at ₹1,374.55. Cipla: Slight upti...
Healthcare Sector Stock Update: Sun Pharma up 1.05%, Cipla up 1.22%, Zydus Lifesciences up 2%
The healthcare sector displayed a varied performance in today’s trading session, with pharmaceutical giants leading gains while hospital operators experienced mixed trends. Gainers: Sun Pharmaceutical...
Nifty 50 top gainers this week: Dr. Reddy’s Laboratories and Cipla shine amid market turmoil
The Indian equity benchmarks, Nifty 50 and Sensex, experienced their sharpest decline in four months on Friday, December 20. The Sensex tumbled 1,176 points, closing at 78,042, while the Nifty 50 drop...
Nifty 50 top gainers today on December 19: Dr. Reddy’s Laboratories, Cipla, Bharat Petroleum and more
Indian benchmark indices continued their downward trend on December 19, marking the fourth consecutive session of losses. At the close, the Sensex dropped by 964.15 points (1.20%) to 79,218.05, while ...
Nifty 50 top gainers today on December 18: Trent, Dr. Reddy’s Laboratories, Cipla and more
On December 18, Indian benchmark indices faced a decline for the third consecutive session, with the Nifty closing below the crucial 24,200 mark. The BSE Sensex fell by 502.25 points, or 0.62%, settli...
Cipla shares surge after Kotak upgrades stock to Buy from Add, target price at Rs 1,725
Cipla’s shares surged 2% after Kotak upgraded the stock to “Buy” from “Add,” with a target price of Rs 1,725, slightly down from the previous Rs 1,750. Despite the anticipated delay in the launch of g...